Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction

New England Journal of Medicine

Volumn 335, Issue 16, 1996, Pages 1198-1205

  Pilote, Louise ^a   Miller, Dave P ^b   Califf, Robert M ^c   Rao, J Sunil ^b   Weaver, W Douglas ^d   Topol, Eric J ^b  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b LERNER RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; FEMALE; FIBRINOLYTIC THERAPY; HEART MUSCLE REVASCULARIZATION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNITED STATES;

AGE FACTORS; AGED; AGED, 80 AND OVER; CORONARY ANGIOGRAPHY; HUMANS; LOGISTIC MODELS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; REGRESSION ANALYSIS; THROMBOLYTIC THERAPY;

EID: 0029794215     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199610173351606     Document Type: Article

References (36)

1. Topol EJ, Holmes DR, Rogers WJ. Coronary angiography after rhrombolytic therapy for acute myocardial infarction. Ann Intern Med 1991;114: 877-85.
2. Rogers WI, Baim DS, Gore JM, et al. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. Circulation 1990;81:1457-76.
3. Barbash GI, Roth A, Hod H, et al. Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:538-45.
4. The TIMI Research Group. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction: TIMI II A results. JAMA 1988;260:2849-58.
5. Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988;1:197-203.
6. Topol EI, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-8.
7. Califf RM, Topol EJ, Stack RS, et al. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: results of Thrombolysis and Angioplasty in Myocardial Infarction - phase 5 randomized trial. Circulation 1991;83:1543-56.
8. Gunnar RM, Bourdillon PD, Dixon DW, et al. ACC/AHA guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures. Circulation 1990;82:664-707.
9. Guidelines for coronary angiography: a report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures. Circulation 1987;76: 963A-977A.
10. Guidelines and indications for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures. J Am Coll Cardiol 1991;17:543-89.
11. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
12. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
13. Lee KL, Califf RM, Simes J, Van de Werf F, Topol EJ. Holding GUSTO up to the light: global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. Ann Intern Med 1994; 120:876-81.
14. Ridker PM, O'Donnell CJ, Marder VJ, Hennekens CH. A response to "holding GUSTO up to the light" Ann Intern Med 1994;120:882-5.
15. American Hospital Association guide to the health care field. 1993 ed. Chicago: American Hospital Association, 1993.
16. Pilote L, Califf RM, Sapp S, et al. Regional variation in the United States for the management of acute myocardial infarction. N Engl J Med 1995;333:565-72.
17. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Belmont, Calif.: Wadsworth International Group, 1984.
18. Chambers IM, Hastie TJ. Statistical models in S. New York: Chapman & Hall, 1993:414.
19. Spertus JA, Weiss NS, Every NR, Weaver WD. The influence of clinical risk factors on the use of angiography and revascularization after acute myocardial infarction. Arch Intern Med 1995;155:2309-16.
20. Henning H, Gilpin EA, Covell JW, Swan EA, O'Rourke RA, Ross J Jr. Prognosis after acute myocardial infarction: a multivariate analysis of mortality and survival. Circulation 1979;59:1124-36.
21. The International Study Group. In hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-5.
22. Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994;90:2645-57.
23. Pryor DB, Shaw LK, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med 1993;118:81-90.
24. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation 1995;91:1659-68.
25. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994;344:563-70. [Erratum, Lancet 1994;344:1446.]
26. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation 1995;91:476-85.
27. Califf RM, Harrell FE Jr, Lee KL, et al. The evolution of medical and surgical therapy for coronary artery disease: a 15-year perspective. JAMA 1989;261:2077-86.
28. Alderman EL, Bourassa MG, Cohen LS, et al. Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation 1990;82:1629-46.
29. Every NR, Larson EB, Litwin PE, et al. The association between onsite cardiac catheterization facilities and the use of coronary angiography after acute myocardial infarction. N Engl J Med 1993;329:546-51.
30. Blustein J. High-technology cardiac procedures: the impact of service availability on service use in New York State. JAMA 1993;270:344-9.
31. Ferguson JJ. Meeting highlights, American Heart Association 68th Scientific Sessions, Anaheim, California, November 13 to 15, 1995. Circulation 1996;93:843-6.
32. Detre KM, Peduzzi P, Hammermeister KE, Murphy ML, Hultgren HN, Takaro T. Five-year effect of medical and surgical therapy on resting left ventricular function in stable angina: Veterans Administration Cooperative Study. Am J Cardiol 1984;53:444-50.
33. Holmes DR Jr, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. J Am Coll Cardiol 1995;26:668-74.
34. Meyer J, Mers W, Dorr R, Lambertz H, Bethge C, Effert S. Successful treatment of acute myocardial infarction shock by combined percutaneous transluminal coronary recanalization (PTCR) and percutaneous transluminal coronary angioplasty (PTCA). Am Heart J 1982;103:132-4.
35. Lee L, Bates ER, Pitt B, Walton JA, Laufer N, O'Neill WW. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988;78:1345-51.
36. Granger CB, Califf RM, Armstrong PW, et al. Noninvasive testing is done only in low risk patients with unstable angina and non-Q-wave myocardial infarction (MI): results from GUSTO-IIa. J Am Coll Cardiol 1996;27:Suppl:181A. abstract.